Golden Ticket Programs

The 2022 Bakar Labs Golden Ticket, in Collaboration With AbbVie

A decorative graphic with text "Golden Ticket to Bakar Labs One Year Free Rent"

Congratulations to Nosis Bio, Radar Therapeutics, and ResVita Bio on their awards. Applications are now closed.


Bakar Labs
Win lab space for a year at Bakar Labs, the flagship life science incubator at UC Berkeley’s Bakar BioEnginuity Hub.

AbbVie and Bakar Labs invite entrepreneurial scientists and founders to apply for a 2022 Bakar Labs Golden Ticket. The Golden Ticket provides lab bench and core facilities at Bakar Labs for one year and opportunities to engage with AbbVie scientific and business leaders. Two Golden Tickets will be awarded to early-stage companies developing novel, transformational therapies in the areas of immunology, oncology, neuroscience, eye care and aesthetics. Additional areas of interest are companies developing breakthrough platforms and technologies, including gene therapy, novel cell therapy, gene editing, or drug discovery technologies.

For complete information on AbbVie’s areas of focus, click here.

Applications are now closed.

The Golden Ticket program is intended to be transformational for your company. In your application, please address how a Golden Ticket would impact your company’s aims.

Selected applicants will be invited to present their company onsite, in person to a select group of Bakar Labs advisors and AbbVie leadership on Thursday, October 20.


Applications are due by Friday, September 23.

Applicants on the shortlist will be notified by Tuesday, October 4.

The shortlist will present to the judging panel in person at Bakar Labs on Thursday, October 20.

The winner will be announced immediately following the pitch session.


This competition is open to life science entrepreneurs who are commercializing, or intend to commercialize, technologies addressing needs in immunology, oncology, neuroscience, eye care, aesthetics and breakthrough platforms and technologies (i.e. gene therapy, novel cell therapy, gene editing, drug discovery technologies, etc.). See full details of AbbVie’s areas of focus

Companies with university affiliation are eligible; so are companies that have no university affiliation.

Teams at the pre-commercial (i.e. not yet incorporated) stage are eligible.

Companies seeking seed-stage through Series A funding are eligible.

We are looking for companies for whom winning a Golden Ticket will significantly impact their ability to advance.

We intend that the winning company use this lab space as its primary site of operations.